Last reviewed · How we verify
Paxipam (HALAZEPAM)
Paxipam (Halazepam) is a small molecule halazepam that targets the GABA-A receptor, an anion channel. It was originally developed by Schering and is currently owned by the same company. Paxipam is FDA-approved for the treatment of anxiety and is off-patent, meaning it is no longer protected by active patents. As a result, there are currently no generic manufacturers of the drug. Paxipam's commercial status and availability may be subject to change.
At a glance
| Generic name | HALAZEPAM |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | halazepam |
| Target | GABA-A receptor; anion channel |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Anxiety
Common side effects
Drug interactions
- ritonavir
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paxipam CI brief — competitive landscape report
- Paxipam updates RSS · CI watch RSS
- Merck & Co. portfolio CI